When the U.S. Food and Drug Administration (FDA) approved a new oral immunotherapy (OIT) for peanut allergy in children on January 31, 2020, it marked an important milestone. This biologic OIT drug, called PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-DNFP], became the first treatment approved by the FDA for people who are allergic to peanuts.
Today in America racial inequality is a great concern for everyone. This article shows immediate need for more research studies; only with accurate data can the food allergy community develop an effective program of action to aid indigent children and other minority children. They need improved access to appropriate childcare, safe food, medical care, and lifesaving medicine like epinephrine for them. Please see more details by clicking here.
As Emily Brown stood in a food pantry looking at her options, she felt alone. Up to that point, she had never struggled financially. But there she was, desperate to find safe food for her young daughter with food allergies. What she found was a jar of salsa and some potatoes. “That was all that was available,” said Brown, who lives in Kansas City, Kansas. “It was just a desperate place.”
When she became a parent, Brown left her job for lack of childcare that would accommodate her daughter’s allergies to peanuts, tree nuts, milk, eggs, wheat, and soy. When she and her husband then turned to a federal food assistance program, they found few allowable allergy substitutions. The closest allergy support group she could find was an hour away. She was almost always the only Black parent, and the only poor parent, there.
This year the Food and Drug Administration (FDA) has made important decisions affecting all Americans. Improving all package labelling to better informing consumers about food allergens is a major priority for our association.
The Food and Drug Administration (FDA) sent proposed guidance “Voluntary Disclosure of Sesame as an Allergen: Guidance for Industry” to the Office of Management and Budget (OMB) for review. While this voluntary guidance falls short of the mandatory sesame allergen labeling that we have been advocating for, we feel it is a promising step in the right direction. This is a result of the FDA’s 2018 request for comments from the public on sesame allergy and their review of those comments from the food allergy community.
Every year the Allergy Advocacy Association Action Awards honor individuals that personify our program of Awareness, Alertness and Action.
Gala Will Honor 2020 Action Awards Winners
Jared Saiontz and S. Shahzad Mustafa, MD win awards
By Jon Terry
October 15th, 2020
"Activists need to be change agents," says William Moyer, a founding member of the Movement for a New Society. "They work to educate, organize, and involve the general public to actively seek positive, constructive solutions to difficult problems."
After many months of activism and advocacy, important legislation is progressing through the US Congress helping central schools across America better protect and support students at risk for dangerous allergic reactions.
Allergy & Asthma Network today applauds the U.S. House of Representatives for passing the School-Based Allergies and Asthma Management Program Act, H.R. 2468 — but our work is not done!
The legislation, long a priority for Allergy & Asthma Network and a host of health and patient organizations, now heads to the U.S. Senate for consideration. The Network will continue its advocacy efforts, urging passage of the bill before the end of the year so it becomes law.